Clinical Trials on Cholangiocarcinoma in Hong Kong
Total 13 results
-
Chinese University of Hong KongCompleted
-
Chinese University of Hong KongTerminatedPancreatic Cancer | CholangiocarcinomaHong Kong
-
Chinese University of Hong KongCompletedCholangiocarcinoma | Klatskin Tumor | TumorHong Kong
-
Arbele Pty LtdRecruitingGastric Cancer | Pancreatic Cancer | Cholangiocarcinoma | Esophageal Adenocarcinoma | Gastrointestinal Cancer | Liver Cancer | Colorectal Adenocarcinoma | Gastroesophageal JunctionHong Kong, Australia
-
PfizerTerminatedAdvanced Breast Cancer (Parts 1 and 2) | Advanced Pancreatic Cancer (Part 1) | Advanced Colorectal Cancer (Part 1) | Advanced Cholangiocarcinoma (Part 1) | Advanced Glioblastoma Multiforme (Part 1)United States, Spain, Hong Kong, Belgium, Australia, France
-
Soon Chun Hyang UniversityUnknownBile Duct Obstruction | Klatskin's TumorKorea, Republic of
-
Relay Therapeutics, Inc.Active, not recruitingCholangiocarcinoma | Intrahepatic Cholangiocarcinoma | FGFR2 Gene Mutation | FGFR2 Amplification | FGFR2 Gene Fusion/Rearrangement | FGFR2 Gene Translocation | FGFR2 Gene Activation | Other Solid Tumors, AdultUnited States, France, Italy, United Kingdom, Korea, Republic of, Spain, Taiwan, Sweden, Germany, Netherlands, Singapore, Australia, Hong Kong
-
Taiho Oncology, Inc.Active, not recruitingAdvanced Cholangiocarcinoma | FGFR2 Gene RearrangementsUnited States, Spain, United Kingdom, Australia, Taiwan, Italy, France, Korea, Republic of, Belgium, Japan, Thailand, Germany, Brazil, Peru, Portugal, Argentina, Hong Kong, Mexico, Netherlands, Poland
-
Eli Lilly and CompanyLoxo Oncology, Inc.Active, not recruitingGlioma | Cholangiocarcinoma | Chondrosarcoma | Any Solid TumorUnited States, Spain, Korea, Republic of, Australia, Japan, Taiwan, France, Singapore, Hong Kong
-
Taiho Oncology, Inc.CompletedBreast Cancer | Gastric Cancer | Cholangiocarcinoma | Urothelial Cancer | Primary CNS Tumors | Advanced and Metastatic Cancer Patients With Tumors Harboring FGF/FGFR TumorsFrance, United States, Korea, Republic of, United Kingdom, Japan, Hong Kong, Australia, Taiwan, Italy, Canada, Germany, Netherlands, Spain
-
MacroGenicsCompletedCervical Cancer | Hematologic Neoplasms | Ovarian Cancer | Non Small Cell Lung Cancer | Advanced Solid Tumors | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Small-cell Lung Cancer | TNBC - Triple-Negative Breast Cancer | HER2-positive Advanced Solid TumorsHong Kong, United States, Thailand, Australia, Spain, Bulgaria, Poland, Ukraine
-
xCuresCancer CommonsAvailableExpanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered MalignanciesMelanoma | Head and Neck Cancer | Glioblastoma | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Small Bowel Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Cholangiocarcinoma | Bladder Cancer | Thyroid Cancer | ERK Mutation | MAPK Gene Mutation | KRAS Activating... and other conditionsUnited States
-
Hoffmann-La RocheActive, not recruitingMelanoma | Renal Cell Carcinoma | Adult Solid Tumor | Breast Cancer | Head and Neck Neoplasms | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Neuroendocrine Tumors | Lymphoma, Large-Cell, Anaplastic | Cholangiocarcinoma | Papillary Thyroid Cancer | Sarcomas | Salivary Gland Cancers and other conditionsUnited States, China, Korea, Republic of, Australia, Taiwan, France, Spain, United Kingdom, Hong Kong, Belgium, Italy, Germany, Japan, Singapore, Netherlands, Poland